Release Part A 16-week proof-of-concept data from Phase 2 APEX trial of APG777
Delivered after the deadline (7 days after the deadline)
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 3 Feb 2025
- Due
- 30 Jun 2025
- Delivered
- 7 Jul 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Part A 16-week proof-of-concept data anticipated in mid-2025”
What we found
Evidence strength B What the grades mean
Apogee announced positive Part A 16-week APEX data on July 7, 2025, roughly one week after the stated mid-2025 (June 30) deadline.
-
B Apogee Therapeutics Provides Business Update, Q1 2025 Financial Results Reaffirms mid-2025 timeline for Part A 16-week data prior to actual release
-
B SEC Form 8-K - Apogee Therapeutics 8-K confirms data release and press release date of July 7, 2025
-
B Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777 Press release announcing Part A 16-week data delivered July 7, 2025
Checked 12 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Commercial launch
- Indicative materiality
- Medium rules
- Action
- Release
- Language
- Expected (“expects”, “plans”)
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
- Second checkThe evidence document could not be read for a second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Apogee Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-APGE-000082 · Corrections policy